Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

s of $3.2 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements regarding the potential for commercializing tolevamer in the future, when data from this Phase 3 study of tolevamer will be presented and when the results of the second Phase 3 study of tolevamer will be available. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, the actual safety and efficacy of tolevamer; the outcome of discussions with regulatory authorities regarding clinical studies and the approval of tolevamer for CDAD and the timing of such discussions; additional analysis of the data from the first Phase 3 study; the results of the second Phase 3 study and whether such results are consistent with this data; the timing of the second Phase 3 study; and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the qu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... CHICAGO, Nov. 29, 2011  In a new study presented today ... America (RSNA), growth hormone replacement for six months was found ... "This is the first time that the effects of growth ... study,s lead author, Miriam A. Bredella, M.D., a radiologist at ...
... Nov. 29, 2011  Newly developed computer software combined with magnetic ... assess a woman,s potential for a difficult childbirth. Results of ... the annual meeting of the Radiological Society of North America ... and not much wider than a fetus,s head, a baby ...
Cached Medicine Technology:Growth Hormone Increases Bone Formation in Obese Women 2Virtual Childbirth Simulator Improves Safety of High-Risk Deliveries 2Virtual Childbirth Simulator Improves Safety of High-Risk Deliveries 3
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period ... for Research (AIR) finds that three out of four Americans ... 42 percent say they are not likely or only somewhat ... coverage. , The AIR survey found wide gaps in Americans’ ... correctly how much they owe for a routine doctor’s visit. ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Haelle HealthDay Reporter , TUESDAY, ... adult men may lead to increased blood pressure, according to ... similar rise in blood pressure for young adult women or ... adult women drank lightly or moderately, their risk of high ... "This finding parallels studies in older adult men and women," ...
(Date:10/22/2014)... Thompson HealthDay Reporter TUESDAY, Oct. ... with Ebola while working for NBC News in Liberia ... special isolation unit at Nebraska Medical Center in Omaha, where he ... Tuesday. A blood test confirmed by the U.S. Centers for ... home to Providence, R.I., NBC News reported Tuesday night. ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... Prix Galien USA Names HUMIRA Best Biotechnology Product, ... (NYSE:,ABT), a leader in the treatment of autoimmune ... Biotechnology Product for HUMIRA (R),(adalimumab), the first approved ... the treatment of moderate to severe rheumatoid arthritis,psoriatic ...
... Powerful New Combination Treatment Option Reduces Mean Systolic Blood ... ... Sept. 27, 2007 Daiichi Sankyo, Inc.,announced today that the ... and olmesartan medoxomil) for the,treatment of hypertension, also known as ...
... CHURCH, Va., Sept. 27 The National,Legal and Policy ... General Motors (GM) and the United Auto Workers (UAW) ... to a fund,controlled by the union., Dr. Carl ... of Union Corruption Update, reacted by saying, "This is,a ...
... Fastest ... Southeast ... Michigan, PONTIAC, Mich., Sept. 27 Continuing its status ... Care is pleased to announce the addition of POH Medical,Center to its network of ...
... Krimpets Will Benefit Online ... Support and Information, PHILADELPHIA, Sept. 27 Tasty ... the,Tastykake Strawberry Jelly Krimpet. 10% of the proceeds from ... to breastcancer.org, a,Narberth, Pennsylvania based online resource dedicated to ...
... Says NCPA Study, DALLAS, Sept. 27 The ... so rapidly that these benefits,are now the fastest rising ... the rate of retirement benefits, according to a new,analysis ... a separate,study also released today, the NCPA says Chile,s ...
Cached Medicine News:Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 2Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 3Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 4Health News:Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care 5Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 2Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 3Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 4Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 5Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 6Health News:McLaren Health Care Adds POH Medical Center to System 2Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 2Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 3Health News:Disability System Sorely in Need of Reform 2Health News:Disability System Sorely in Need of Reform 3
... 96 well thermocycler with ... Peltier technology for fastest available ... to 4C/sec with High Pressure ... PCR plates. Includes motorized ...
... Faster speeds, highest precision, more ... flexible concept: this is the definition of ... few years nucleic acid research has been ... capabilities required of PCR Systems. To ...
... The Techne TC412 is a high performance, high ... Features & Benefits include: Flexible block ... programming, 8 peltiers, PC networking. Includes a ... to 32 Techne cyclers can be connected and ...
... The Tetrad 2 thermal cycler incorporates ... Research Tetrad chassis. As before, the chassis ... power supply is internal, while a large, color ... yet, updated automatic lids -- Moto Alphas -- ...
Medicine Products: